(Q40485566)

English

Formestane. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of breast cancer and prostatic cancer

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

20 September 2017

1 reference

Europe PubMed Central

Formestane. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of breast cancer and prostatic cancer (English)

1 reference

Europe PubMed Central

20 September 2017

pharmacodynamics

1 reference

based on heuristic

inferred from title

author name string

L R Wiseman

1

1 reference

Europe PubMed Central

20 September 2017

D McTavish

2

1 reference

Europe PubMed Central

20 September 2017

publication date

1 January 1993

1 reference

Europe PubMed Central

20 September 2017

1 reference

Europe PubMed Central

20 September 2017

45

1 reference

Europe PubMed Central

20 September 2017

66-84

1 reference

Europe PubMed Central

20 September 2017

1

1 reference

Europe PubMed Central

20 September 2017

https://scigraph.springernature.com/pub.10.2165/00003495-199345010-00007

0 references

Failure of human benign prostatic hyperplasia to aromatise testosterone

1 reference

https://pubmed.ncbi.nlm.nih.gov/7680986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparative studies of aromatase inhibitors in relation to the significance of estrogen synthesis in human mammary tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/7680986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antibodies to 4-hydroxyandrostenedione--a new anti-breast cancer agent suitable for use in a radioimmunoassay

1 reference

https://pubmed.ncbi.nlm.nih.gov/7680986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The inhibition of human prostatic aromatase activity by imidazole drugs including ketoconazole and 4-hydroxyandrostenedione.

1 reference

https://pubmed.ncbi.nlm.nih.gov/7680986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/7680986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quantitative determination of 4-hydroxy-4-androstene-3,17-dione (4-OHA), a potent aromatase inhibitor, in human plasma, using isotope dilution mass spectrometry

1 reference

https://pubmed.ncbi.nlm.nih.gov/7680986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/7680986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

4-Hydroxyandrostenedione treatment for postmenopausal patients with advanced breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/7680986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of aromatase inhibitors, aminoglutethimide, and 4-hydroxyandrostenedione on cyclic rats and rats with 7,12-dimethylbenz(a)anthracene-induced mammary tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/7680986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Response of nitrosomethylurea-induced rat mammary tumor to endocrine therapy and comparison with clinical response

1 reference

https://pubmed.ncbi.nlm.nih.gov/7680986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identification of 4-hydroxyandrost-4-ene-3,17-dione metabolites in prostatic cancer patients by liquid chromatography-mass spectrometry

1 reference

https://pubmed.ncbi.nlm.nih.gov/7680986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Aminoglutethimide for the treatment of advanced postmenopausal breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/7680986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

4-Hydroxyandrostenedione in the prophylaxis of N-methyl-N-nitrosourea induced mammary tumourigenesis

1 reference

https://pubmed.ncbi.nlm.nih.gov/7680986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lack of evidence for aromatase in human prostatic tissues: effects of 4-hydroxyandrostenedione and other inhibitors on androgen metabolism

1 reference

https://pubmed.ncbi.nlm.nih.gov/7680986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Aromatase activity in genital skin fibroblasts from normal and androgen-insensitive individuals

1 reference

https://pubmed.ncbi.nlm.nih.gov/7680986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

3 beta-hydroxyandrost-4-en-6-one derivatives as aromatase inhibitors

1 reference

https://pubmed.ncbi.nlm.nih.gov/7680986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of the pharmacokinetics and pharmacodynamics of unformulated and formulated 4-hydroxyandrostenedione taken orally by healthy men

1 reference

https://pubmed.ncbi.nlm.nih.gov/7680986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Aromatase inhibition in advanced prostatic cancer: preliminary communication.

1 reference

https://pubmed.ncbi.nlm.nih.gov/7680986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An endocrine and pharmacokinetic study of four oral doses of formestane in postmenopausal breast cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/7680986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The possibility of aromatization of androgen in human prostate

1 reference

https://pubmed.ncbi.nlm.nih.gov/7680986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Radioimmunoassay of the anti-cancer agent 4-hydroxyandrostenedione in body fluids

1 reference

https://pubmed.ncbi.nlm.nih.gov/7680986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of peripheral aromatization by aromatase inhibitors, 4-hydroxy- and 4-acetoxy-androstene-3,17-dione

1 reference

https://pubmed.ncbi.nlm.nih.gov/7680986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of advanced breast cancer in postmenopausal women with 4-hydroxyandrostenedione

1 reference

https://pubmed.ncbi.nlm.nih.gov/7680986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

4-Aminoandrostenedione derivatives: a novel class of irreversible aromatase inhibitors. Comparison with FCE 24304 and 4-hydroxyandrostenedione

1 reference

https://pubmed.ncbi.nlm.nih.gov/7680986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Metabolism of the aromatase inhibitor 4-hydroxyandrostenedione in vivo. Identification of the glucuronide as a major urinary metabolite in patients and biliary metabolite in the rat.

1 reference

https://pubmed.ncbi.nlm.nih.gov/7680986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Determination of 4-hydroxyandrost-4-ene-3,17-dione metabolism in breast cancer patients using high-performance liquid chromatography-mass spectrometry

1 reference

https://pubmed.ncbi.nlm.nih.gov/7680986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Concentrations of oestrone and 4-hydroxyandrostenedione in malignant and normal breast tissues

1 reference

https://pubmed.ncbi.nlm.nih.gov/7680986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Aromatase inhibitors and the treatment of breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/7680986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Utilization of oxygen and reduced nicotinamide adenine dinucleotide phosphate by human placental microsomes during aromatization of androstenedione

1 reference

https://pubmed.ncbi.nlm.nih.gov/7680986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The influence of 4-hydroxy-4-androstene-3,17-dione on androgen metabolism and action in cultured human foreskin fibroblasts

1 reference

https://pubmed.ncbi.nlm.nih.gov/7680986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: phase II report

1 reference

https://pubmed.ncbi.nlm.nih.gov/7680986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparative studies of aromatase inhibitors in cultured human breast cancer cells.

1 reference

https://pubmed.ncbi.nlm.nih.gov/7680986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Response to endocrine manipulation and oestrogen receptor concentration in large operable primary breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/7680986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Aromatase inhibition with 4-hydroxyandrostenedione in the treatment of postmenopausal patients with advanced breast cancer: a phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/7680986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Response to aminoglutethimide and cortisone acetate in advanced prostatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/7680986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Aromatase inhibition: 4-hydroxyandrostenedione (4-OHA, CGP 32349) in advanced prostatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/7680986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Aromatase enzyme catalysis is involved in the potent inhibition of estrogen biosynthesis caused by 4-acetoxy- and 4-hydroxy-4-androstene-3, 17-dione

1 reference

https://pubmed.ncbi.nlm.nih.gov/7680986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oral 4-hydroxyandrostenedione, a new endocrine treatment for disseminated breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/7680986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inactivation of aromatase in vitro by 4-hydroxy-4-androstene-3,17-dione and 4-acetoxy-4-androstene-3,17-dione and sustained effects in vivo

1 reference

https://pubmed.ncbi.nlm.nih.gov/7680986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Aromatase inhibition by an enzyme-activated irreversible inhibitor in human carcinoma cell cultures

1 reference

https://pubmed.ncbi.nlm.nih.gov/7680986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A simple, inexpensive, and precise microcell for the exchange dialysis and equilibrium dialysis of small samples

1 reference

https://pubmed.ncbi.nlm.nih.gov/7680986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Correlation of breast tumour aromatase activity and response to aromatase inhibition with aminoglutethimide

1 reference

https://pubmed.ncbi.nlm.nih.gov/7680986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The Effect of an Aromatase Inhibitor, 4-Hydroxy-4-Androstene- 3,17-Dione, On Estrogen-Dependent Processes in Reproduction and Breast Cancer11

1 reference

https://pubmed.ncbi.nlm.nih.gov/7680986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/7680986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Imidazole antimycotics: selective inhibitors of steroid aromatization and progesterone hydroxylation

1 reference

https://pubmed.ncbi.nlm.nih.gov/7680986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Detection of intratumoral aromatase in breast carcinomas. An immunohistochemical study with clinicopathologic correlation

1 reference

https://pubmed.ncbi.nlm.nih.gov/7680986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vivo and in vitro pharmacological studies of aminoglutethimide as an aromatase inhibitor

1 reference

https://pubmed.ncbi.nlm.nih.gov/7680986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route

1 reference

https://pubmed.ncbi.nlm.nih.gov/7680986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of aromatase inhibitor 4-hydroxyandrostenedione and other compounds in the 7, 12-dimethylbenz(a)anthracene-induced breast carcinoma model.

1 reference

https://pubmed.ncbi.nlm.nih.gov/7680986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of treatment with 4-hydroxyandrostenedione on the peripheral conversion of androstenedione to estrone and in vitro tumor aromatase activity in postmenopausal women with breast cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/7680986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biological significance of aromatase activity in human breast tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/7680986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Steroid modulation of aromatase activity in human cultured breast carcinoma cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/7680986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

4-hydroxyandrostenedione--further clinical and extended endocrine observations

1 reference

https://pubmed.ncbi.nlm.nih.gov/7680986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of 4-hydroxy-4-androstene-3,17-dione and 10-propargylestr-4-ene-3,17-dione on the metabolism of androstenedione in human breast carcinoma and breast adipose tissues

1 reference

https://pubmed.ncbi.nlm.nih.gov/7680986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

4-hydroxyandrostenedione: a new treatment for postmenopausal patients with breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/7680986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Structure-activity relationships of the inhibition of human placental aromatase by imidazole drugs including ketoconazole

1 reference

https://pubmed.ncbi.nlm.nih.gov/7680986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of androgen aromatization in human breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/7680986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Aromatase inhibitors. Synthesis and biological activity of androstenedione derivatives

1 reference

https://pubmed.ncbi.nlm.nih.gov/7680986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/00003495-199345010-00007

1 reference

Europe PubMed Central

20 September 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

20 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40485566&oldid=2144224700"